Persistence of antibodies after full vaccination course with GSK Biologicals' Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age

Trial Profile

Persistence of antibodies after full vaccination course with GSK Biologicals' Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib-DTaP-hepatitis B-poliovirus vaccine; Meningococcal vaccine group C conjugate; Pneumococcal 10-valent vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Nov 2013 New source identified and integrated (ClinicalTrials.gov; NCT00891176).
    • 27 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top